Advertisement
Advertisement
U.S. Markets open in 2 hrs 51 mins
Advertisement
Advertisement
Advertisement
Advertisement

Nabriva Therapeutics plc (NBRV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1935+0.0035 (+1.84%)
At close: 04:00PM EDT
0.1817 -0.01 (-6.10%)
Pre-Market: 05:52AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1900
Open0.1952
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range0.1900 - 0.2144
52 Week Range0.1560 - 1.4000
Volume3,611,762
Avg. Volume806,093
Market Cap10.975M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-1.6220
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • GlobeNewswire

    Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

    - Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the completion of patient enrollment in its Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA® (lefamulin) in adult patients with cystic fib

  • GlobeNewswire

    Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

    -Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2022 and provided a corporate upda

  • GlobeNewswire

    Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

    DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022. Nabriva’s management will host a conference call at 4:3

Advertisement
Advertisement